rucaparib,abiraterone,enzalutamide
pfizer,astellas,clovis oncology
['rucaparib', 'brca', 'crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'triton3']
more data showing the benefits of #parp inhibitors. #triton3 by showing benefit to #rucaparib for 2nd line mcrpc. 75% had #brca mutations. unsurprising no benefits for #atm mutations. os trending but not fully mature yet. #gu23 
Editor Emeritus of @pcan_journal; Dir of CIRCL, studying effects of lifestyle choices on cancer risk and progression; AD Education/Training @CSCancerCare.